The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice
- PMID: 12379729
- PMCID: PMC130407
- DOI: 10.1128/IAI.70.11.6464-6467.2002
The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice
Abstract
We expressed three Actinobacillus pleuropneumoniae ApxI deletion derivatives to map the domain that could induce protective immunity. Antiserum to ApxI N-terminal covered by residues 40 to 380 was found to neutralize ApxI hemolytic activity but not ApxIII cytotoxicity. When used as a subunit vaccine in mice, this recombinant N-terminal fragment elicited protection against lethal infection with heterologous A. pleuropneumoniae serovars.
Figures



Similar articles
-
Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.Vet Immunol Immunopathol. 2013 Jan 15;151(1-2):102-12. doi: 10.1016/j.vetimm.2012.10.011. Epub 2012 Nov 9. Vet Immunol Immunopathol. 2013. PMID: 23200821
-
Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.Acta Vet Scand. 2010 Sep 11;52(1):52. doi: 10.1186/1751-0147-52-52. Acta Vet Scand. 2010. PMID: 20831818 Free PMC article.
-
Development of Actinobacillus pleuropneumoniae ApxI, ApxII, and ApxIII-specific ELISA methods for evaluation of vaccine efficiency.J Vet Sci. 2019 Mar;20(2):e2. doi: 10.4142/jvs.2019.20.e2. Epub 2019 Feb 19. J Vet Sci. 2019. PMID: 30944525 Free PMC article.
-
New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.Vet Microbiol. 2018 Apr;217:66-75. doi: 10.1016/j.vetmic.2018.02.028. Epub 2018 Mar 6. Vet Microbiol. 2018. PMID: 29615259 Review.
-
Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies.Anim Health Res Rev. 2008 Jun;9(1):25-45. doi: 10.1017/S1466252307001338. Epub 2008 Mar 17. Anim Health Res Rev. 2008. PMID: 18346296 Review.
Cited by
-
Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice.J Vet Sci. 2007 Dec;8(4):383-92. doi: 10.4142/jvs.2007.8.4.383. J Vet Sci. 2007. PMID: 17993753 Free PMC article.
-
Immunoproteomic analysis of bacterial proteins of Actinobacillus pleuropneumoniae serotype 1.Proteome Sci. 2011 Jun 26;9(1):32. doi: 10.1186/1477-5956-9-32. Proteome Sci. 2011. PMID: 21703014 Free PMC article.
-
Polymorphism analysis of the apxIA gene of Actinobacillus pleuropneumoniae serovar 5 isolated in swine herds from Brazil.PLoS One. 2018 Dec 18;13(12):e0208789. doi: 10.1371/journal.pone.0208789. eCollection 2018. PLoS One. 2018. PMID: 30562362 Free PMC article.
-
Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice.AMB Express. 2020 Jul 8;10(1):123. doi: 10.1186/s13568-020-01051-1. AMB Express. 2020. PMID: 32642871 Free PMC article.
-
Draft Genome Sequence of the Virulent Avibacterium paragallinarum Serotype A Strain JF4211 and Identification of Two Toxins.Genome Announc. 2013 Aug 15;1(4):e00592-13. doi: 10.1128/genomeA.00592-13. Genome Announc. 2013. PMID: 23950117 Free PMC article.
References
-
- Bagdasarian, M. M., M. Nagai, J. Frey, and M. Bagdasarian. 1999. Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E. coli heat-labile enterotoxin B subunit. Vaccine 17:441-447. - PubMed
-
- Blackall, P. J., H. L. Klaasen, H. van den Bosch, P. Kuhnert, and J. Frey. 2002. Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15. Vet. Microbiol. 84:47-52. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources